[
  {
    "ts": null,
    "headline": "Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point",
    "summary": "This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.",
    "url": "https://finnhub.io/api/news?id=6db04e45e76e8db02ca5a9cb90e941d685d83ff62c78c1f028224ba309279d03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763405087,
      "headline": "Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point",
      "id": 137506298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.",
      "url": "https://finnhub.io/api/news?id=6db04e45e76e8db02ca5a9cb90e941d685d83ff62c78c1f028224ba309279d03"
    }
  },
  {
    "ts": null,
    "headline": "How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration",
    "summary": "Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.",
    "url": "https://finnhub.io/api/news?id=21b472c5106e43c25a9415b924933f827dd75994b9361f36cdd5896616769957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763399274,
      "headline": "How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration",
      "id": 137506299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.",
      "url": "https://finnhub.io/api/news?id=21b472c5106e43c25a9415b924933f827dd75994b9361f36cdd5896616769957"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.",
    "summary": "Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.",
    "url": "https://finnhub.io/api/news?id=9803dc282d2f71959a5ebab4b246083e745254f5694c2a551871b5224c6f447d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763396520,
      "headline": "Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.",
      "id": 137506300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.",
      "url": "https://finnhub.io/api/news?id=9803dc282d2f71959a5ebab4b246083e745254f5694c2a551871b5224c6f447d"
    }
  },
  {
    "ts": null,
    "headline": "NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?",
    "summary": "Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.",
    "url": "https://finnhub.io/api/news?id=544ad70a57aaa80ffd74596bc5b43055b057792286403aa452e12ed6efc9073e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763393040,
      "headline": "NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?",
      "id": 137506301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.",
      "url": "https://finnhub.io/api/news?id=544ad70a57aaa80ffd74596bc5b43055b057792286403aa452e12ed6efc9073e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Could Be Next Company to Split Its Stock",
    "summary": "The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.",
    "url": "https://finnhub.io/api/news?id=5f0d331e1633811d3f46a1a03f46905b4ce7878dabd760691263cbfe65da4dfd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763388300,
      "headline": "Eli Lilly Could Be Next Company to Split Its Stock",
      "id": 137506155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.",
      "url": "https://finnhub.io/api/news?id=5f0d331e1633811d3f46a1a03f46905b4ce7878dabd760691263cbfe65da4dfd"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=84ac38ec650f7e501a9214ae97faebf3343fa7357f76f5a26a348ac1e40aee16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763388005,
      "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock",
      "id": 137506303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=84ac38ec650f7e501a9214ae97faebf3343fa7357f76f5a26a348ac1e40aee16"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Cuts Prices for Obesity Drugs",
    "summary": "The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the treatments between Nov. 17 and March 31.",
    "url": "https://finnhub.io/api/news?id=df7653a1a3b40f1baac96ecfe6af0a619167670e18cc8eabee44b96c24188ef3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763387760,
      "headline": "Novo Nordisk Cuts Prices for Obesity Drugs",
      "id": 137506304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the treatments between Nov. 17 and March 31.",
      "url": "https://finnhub.io/api/news?id=df7653a1a3b40f1baac96ecfe6af0a619167670e18cc8eabee44b96c24188ef3"
    }
  },
  {
    "ts": null,
    "headline": "Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ",
    "summary": "Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.",
    "url": "https://finnhub.io/api/news?id=dfd0d4641251f6cdcaa53f6124ac74da2fef75d0661da8b8b3872640a1ed46be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763381280,
      "headline": "Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ",
      "id": 137506305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.",
      "url": "https://finnhub.io/api/news?id=dfd0d4641251f6cdcaa53f6124ac74da2fef75d0661da8b8b3872640a1ed46be"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Jeff Bezos To Co-Lead $6.2B AI Startup",
    "summary": "Amazon (AMZN) founder Jeff Bezos is creating an AI startup that he will help manage as co-chief executive.",
    "url": "https://finnhub.io/api/news?id=adced17a899267bfbab0f013031b5bb82a7a95a0a6f591d08d709e7cb3ee63ea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763375179,
      "headline": "Wall Street Lunch: Jeff Bezos To Co-Lead $6.2B AI Startup",
      "id": 137504853,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2245403031/image_2245403031.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amazon (AMZN) founder Jeff Bezos is creating an AI startup that he will help manage as co-chief executive.",
      "url": "https://finnhub.io/api/news?id=adced17a899267bfbab0f013031b5bb82a7a95a0a6f591d08d709e7cb3ee63ea"
    }
  },
  {
    "ts": null,
    "headline": "This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?",
    "summary": "Healthcare stocks have far outperformed the broader market over the past month.",
    "url": "https://finnhub.io/api/news?id=f22e07239324a46245e0317c46ee7995740a1904fa3b9de49567436a05712f86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763375100,
      "headline": "This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?",
      "id": 137504060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare stocks have far outperformed the broader market over the past month.",
      "url": "https://finnhub.io/api/news?id=f22e07239324a46245e0317c46ee7995740a1904fa3b9de49567436a05712f86"
    }
  },
  {
    "ts": null,
    "headline": "The Club's top 10 things to watch in the stock market Monday",
    "summary": "Stock futures are relatively muted early this morning. The market is coming off a volatile week, driven by doubts about the sustainability of AI spending.",
    "url": "https://finnhub.io/api/news?id=ec2712827bd069539f87cf6a3ae1272d68a0677dae42cd005b604ef60c644c6d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763370143,
      "headline": "The Club's top 10 things to watch in the stock market Monday",
      "id": 137505318,
      "image": "https://image.cnbcfm.com/api/v1/image/108196778-1757507590799-gettyimages-2234563479-_73a3022_jnkqswz6.jpeg?v=1763386323&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Stock futures are relatively muted early this morning. The market is coming off a volatile week, driven by doubts about the sustainability of AI spending.",
      "url": "https://finnhub.io/api/news?id=ec2712827bd069539f87cf6a3ae1272d68a0677dae42cd005b604ef60c644c6d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: This Breakout Rally Has More Room To Run",
    "summary": "Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest analysis of LLY.",
    "url": "https://finnhub.io/api/news?id=0ca4d28d90a18ca4516ab9bef54305ebc5dc1fdb81afe556a7bf9ddb2f871920",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763370000,
      "headline": "Eli Lilly: This Breakout Rally Has More Room To Run",
      "id": 137504582,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest analysis of LLY.",
      "url": "https://finnhub.io/api/news?id=0ca4d28d90a18ca4516ab9bef54305ebc5dc1fdb81afe556a7bf9ddb2f871920"
    }
  },
  {
    "ts": null,
    "headline": "2 Mooning  Stocks to Keep an Eye On and 1 We Ignore",
    "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
    "url": "https://finnhub.io/api/news?id=ebaeeb59641daf0c8b946d4308d3a58afe8927a51e059a0b0f706d2e18ff039e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763354725,
      "headline": "2 Mooning  Stocks to Keep an Eye On and 1 We Ignore",
      "id": 137504061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
      "url": "https://finnhub.io/api/news?id=ebaeeb59641daf0c8b946d4308d3a58afe8927a51e059a0b0f706d2e18ff039e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and (LLY) Price Target Increased by 10.15% to 1,020.92",
    "summary": "Eli Lilly and (LLY) Price Target Increased by 10.15% to 1,020.92",
    "url": "https://finnhub.io/api/news?id=609e1a4f0b9bb9345a78f9a3d7c11a2dcf21a6b0e8721066f01cf5493f27da34",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763351174,
      "headline": "Eli Lilly and (LLY) Price Target Increased by 10.15% to 1,020.92",
      "id": 137501495,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=609e1a4f0b9bb9345a78f9a3d7c11a2dcf21a6b0e8721066f01cf5493f27da34"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts",
    "summary": "With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target. The firm cited upcoming ACCESS I and II Phase 2b […]",
    "url": "https://finnhub.io/api/news?id=d7bf86195d4593f34bbfaab4114bf7919f42c0fc0d3a9e5306006a26cadcf2f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763349243,
      "headline": "BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts",
      "id": 137501967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target. The firm cited upcoming ACCESS I and II Phase 2b […]",
      "url": "https://finnhub.io/api/news?id=d7bf86195d4593f34bbfaab4114bf7919f42c0fc0d3a9e5306006a26cadcf2f2"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Around Eli Lilly Is Evolving After New Analyst Updates and Drug Developments",
    "summary": "Eli Lilly's stock has captured attention as consensus analyst price targets have risen from $919 to $1,003 per share. This shift underscores renewed optimism about the company's valuation prospects. The upward revision largely reflects analysts’ growing confidence in revenue growth, supported by robust demand for key treatments and steady execution across major franchises. As Wall Street continues to update its outlook in response to new data and market dynamics, readers will want to keep an...",
    "url": "https://finnhub.io/api/news?id=31358c8f5314c481226060d405facb807737170bbfbfd9683ed8152f2e2b41fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763341910,
      "headline": "How the Narrative Around Eli Lilly Is Evolving After New Analyst Updates and Drug Developments",
      "id": 137501968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's stock has captured attention as consensus analyst price targets have risen from $919 to $1,003 per share. This shift underscores renewed optimism about the company's valuation prospects. The upward revision largely reflects analysts’ growing confidence in revenue growth, supported by robust demand for key treatments and steady execution across major franchises. As Wall Street continues to update its outlook in response to new data and market dynamics, readers will want to keep an...",
      "url": "https://finnhub.io/api/news?id=31358c8f5314c481226060d405facb807737170bbfbfd9683ed8152f2e2b41fb"
    }
  }
]